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e-mail address: Francis.Munier@fa2.ch (F.L. Munier).Francis L. Munier, MD a,b,⇑; Marie-Claire Gaillard, MD a; Aubin Balmer, MD a; Maja Beck-Popovic, MD cAbstractFor decades intravitreal chemotherapy (IViC) remained virtually banished from the therapeutic armamentarium against retinoblas-
toma, except as a heroic attempt of salvage before enucleation in only eyes with refractory vitreous seeding. Very recently, we
have initiated a reappraisal of this route of administration by (1) profiling eligibility criteria, (2) describing a safety-enhanced injec-
tion procedure, (3) adjusting the tumoricidal dose of melphalan, and (4) reporting an unprecedented efficacy in terms of tumor
control of vitreous seeding. Since then, intravitreal chemotherapy is being progressively implemented worldwide with great suc-
cess, but still awaits formal validation by the ongoing prospective phase II clinical trial. As far as preliminary results are concerned,
IViC appears to achieve complete vitreous response in 100% of the 35 newly recruited patients irrespective of the previous treat-
ment regimen, including external beam radiotherapy and/or intra-arterial melphalan. In other words, vitreous seeding, still consid-
ered as the major cause of primary and secondary enucleation, can now be controlled by IViC. However, sterilization of vitreous
seeding does not necessarily translate into eye survival, unless the retinal source of the seeds receives concomitant therapy. In
conclusion, IViC, an unsophisticated and cost-effective treatment, is about to revolutionize the eye survival prognosis of vitreous
disease in advanced retinoblastoma.
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Despite tremendous advances in the conservative
management of advanced retinoblastoma, the major cause
of failure remains the persistence or recurrence of resistant
vitreous seeding. Vitreous seeds result from the clonal selec-
tion of retinoblastoma cells that are able to proliferate in the
avascular vitreous environment. Cells surviving in such hypoxic
conditions are prone to develop chemo-resistance propertiesbeyond all classic therapeutic modalities. Pharmacokinetic
studies have recently shown that, if the novel routes of admin-
istration such as peri-ocular and intra-arterial chemotherapy
have greatly improved the ocular penetration of the drugs
compared to systemic chemotherapy, the achieved vitreous
concentration is barely tumoricidal, and does not last long en-
ough for tumor control. One way to deliver the desired vitre-
ous drug concentration would be to perform intravitreal
chemotherapy. However, as with any invasive procedure,e:
al.com
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ment of retinoblastoma, due to the risk of loco-regional and
systemic tumor spread.Conditional rehabilitation of intravitreal
chemotherapy
In the light of these data, we have decided to revisit the fea-
sibility of injecting the chemotherapeutic agent directly into
the vitreous cavity through the pars plana as the best way to
achieve the appropriate drug concentration. As a first step
we have tested the value of ultrasonic bio-microscopic (UBM)
imaging of the anterior segment, using a 35 mHz transducer,
to predict the safety of a pars plana route of administration.
This allowed us to show that tumoral contamination of the pos-
terior chamber can be assessed by UBM with high sensibility
and specificity even in the absence of anterior chamber
involvement.1 Our next step was to profile the safety of intra-
vitreal injections for retinoblastoma by parametring all risk fac-
tors for tumor spread and by designing an injection technique
minimizing the addressed risks.2 These preliminary studies
paved the way to the first report on efficacy of intravitreal che-
motherapy for vitreous disease in retinoblastoma as an alter-
native to enucleation or external beam radiotherapy.3
Here below we describe the state of the art procedure for
intravitreal chemotherapy including diagnosis considerations,
prevention of tumor spread, technical issues and monitoring
of the response to treatment.Diagnosis considerations
IViC should not be performed unless a) the tumoral nature
of the seeding is unequivocal and differentiated from other
mimicking conditions, such as old vitreous hemorrhage or
vitritis, b) the tumoral viability of the seeding is obvious,
which can sometimes require an observation period to docu-
ment the vitreous growth. Finally the retinal source of the
seeding must be identified and, if still active, must be con-
comitantly eradicated.Prevention of tumor spread
The underlying mechanisms leading to tumor spread can
be classified into two categories, passive per-operative and
active post-operative. Passive per-operative tumor spread
may occur due to the spilling of tumor cells adherent to sur-
gical instruments when removed from the eye, or to theFigure 1. Exclusion UBM criteria: tumor (A), vitreous seeds (B), or retinal detac
chamber (D), or anterior hyaloid detachment (E).reflux of contaminated humors secondary to variations of
intraocular pressure. Active post-operative exteriorization
may occur via tumor growth along a contaminated surgical
wound, or in consequence to co-localization of the entry site
with a parietal tumor. To be effective in preventing extra-ocu-
lar tumor spread, the injection procedure should minimize
both active and passive mechanisms of exteriorization.
Concerning the prevention of active mechanisms of exte-
riorization, UBM-based contra-indications to IViC were iden-
tified (Fig. 1). IViC was considered a threat for survival, and
thus an absolute contra-indication, in the case of parietal tu-
mor or seeding co-localizing with the entry site, especially if
the posterior chamber is invaded. IViC was considered as a
threat for eye survival, and thus a relative contra-indication,
in the case of anterior hyaloid or retinal detachment at the
meridian of the entry site. The risk here is to convert a) vitre-
ous seeding to anterior segment seeding through the perfo-
rated hyaloid, or b) exudative retinal detachment to the
rhegmatogenous form. This is also the reason why we ex-
cluded other injection routes of administration other than
the pars plana, such as the trans-corneal approach. Specifi-
cally, the technique of injection through the peripheral cor-
nea and iris root not only creates perforation of the cornea
but also perforation of the iris and anterior hyaloid. If the first
can be secured by cryotherapy, the risk of contamination re-
mains for the latter two, the worst being the creation of a
communication between the vitreous cavity and the posterior
chamber. The danger is real since anyone who has performed
intravitreal injections knows that vitreous incarceration
through the sclera can happen while retracting the needle.
The second level of tumor spread prevention is aimed at
addressing all risk factors linked to the per-operative passive
mechanisms of exteriorization, i.e. the gradient of pressure
across the sclera, the size and number of surgical entries,
and the duration of surgery. This lead us to develop a
safety-enhanced injection technique 2, consisting of an anti-
reflux technique and sterilization of the needle tract. Specifi-
cally, we first create a transient hypotony by an anterior
chamber paracentesis, aspirating the same volume as the
one to be injected into the vitreous. The injection itself is per-
formed using a 32G needle, lasts no more than 15 seconds
and is followed by a triple freeze and thaw cryo-application
to sterilize the pars plana entry site.Technique of injection
An anterior chamber paracentesis is performed before
melphalan injection. A volume of 0.1–0.15 ml (according tohment (C) at the entry site, as well as invasion of the anterior and posterior
Figure 2. Fundus montage at presentation (A) and at treatment completion (B) 7 months later.
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rated and sent for cytopathologic analysis. A 32G needle
mounted on a tuberculin syringe is then introduced perpen-
dicularly 2.5–3.5 mm from the limbus at the desired meridian
opposite the seeds through the conjunctiva and sclera under
microscope viewing until the needle tip reaches the center of
the vitreous cavity. The injected dose is 20 lg in most cases
but can be cumulatively increased by 2–4 lg up to 30 lg
for each of the following situations: (1) age over 2 years; (2)
diffuse nature and/or high density of the seeding; (3) previous
intra-arterial exposure to melphalan and (4) relapse after pre-
vious IViC. Upon removal of the needle three cycles of freeze
and thaw cryoapplications are given at the injection site. The
eye is then carefully shaken with a forceps in all directions to
enable even distribution of the drug.
Follow-up and response monitoring
At each visit the residual vitreous tumor burden is reas-
sessed and IViC carried out every 7–10 days, up to eight
injections if a response can be documented, until complete
seed fragmentation is observed or complete response is
achieved (Fig. 2). Complete response is established if the
seeds (1) completely disappear (vitreous seeding regression
type 0), or convert into (2) refringent and/or calcified residues
(vitreous seeding regression type I), (3) amorphous often
non-spherical inactive residues (vitreous seeding regression
type II), or (4) a combination of the latter two (vitreous seed-
ing regression type III). An injection of consolidation is usually
given once a complete response is observed. IViC can be re-
peated if vitreous recurrence occurs from another source.
Unprecedented tumor control of vitreous seeding
We reported the first case series showing the efficacy and
safety of intravitreal chemotherapy (IViC) in retinoblastoma
patients presenting with vitreous disease.3 Twenty-three con-
secutive heavily pretreated patients presenting vitreous
seeding and eligible for IViC were included in this retrospec-
tive non-comparative study. The study population consisted
of 18 bilaterally affected patients, 10 of whom had only one
eye, and five patients with unilateral retinoblastoma. IViC
was proposed as an alternative to external beam irradiation
or enucleation for recurrent (74%) or refractory (26%) seeds.
Almost 2/3 of this population received intra-arterial melpha-
lan chemotherapy before IViC. Overall, success with controlof vitreous seeds was achieved in 21 of 23 eyes (91%) after
a mean number of four injections. Globe retention was
achieved in 87% of cases with only 2 eyes enucleated for pro-
gressive disease and one for phthisis bulbi unrelated to IViC.
All retained eyes were in complete remission, and there were
no cases of orbital or systemic retinoblastoma recurrence
over a mean 22 months’ follow-up. The Kaplan–Meier esti-
mate of ocular survival rates at 2 years was 84.14% (95% CI
62.48–95.28%). All patients were alive without evidence of
extraocular spread (95% CI 82.19–100%). We have now ex-
tended the follow-up of this initial cohort of 20 conserved
eyes with a mean tumor-free eye survival (unpublished data)
of 32 months (17–42 months).
Retinal toxicity appeared to be limited to the site of injec-
tion in the form of a peripheral well demarcated salt-and-
pepper retinopathy in 10 eyes (43%). In fact, this local toxicity
confined to the site of a higher concentration of melphalan
along the needle passage serves to increase the security level
of the procedure. There was no ophthalmoscopic or fluoro-
angiographic evidence of retinal toxicity at other locations.
Similarly, we failed to detect any optic coherence tomogra-
phy (OCT) changes within the macula after IViC (unpublished
data). A transient localized vitreous hemorrhage in two eyes
(8.5%) was the only ocular complication observed. Specifi-
cally, IViC was not found to cause corneal endothelium insuf-
ficiency, cataract (one case was radiation-induced), uveitis,
endophthalmitis, or retinal detachment.
For the first time the eye retention rate of the worst retino-
blastoma eye group (group D and all cases with recurrent or
refractory vitreous seeding) appeared to parallel that of
groups A–C without external beam radiotherapy.
Conclusions and perspectives
Although IViC appears to offer a safe and efficient salvage
option, its validation awaits the results of a prospective phase
II clinical trial. Special attention will be paid to long term
safety and retinal toxicity assessed by electroretinogram,
fluorescein angiography and OCT. In a preliminary report
we have shown that photopic ERG amplitudes were un-
changed compared with those recorded prior to the intravi-
treal injection treatments.4
In order to prospectively investigate the role of IViC in the
management of vitreous disease, we have launched a phase II
clinical trial SPOG-RB-2011 (EudraCT number 2013-002006-
31) in collaboration with other centers. Basically, this protocol
150 F.L. Munier et al.is proposing three treatments modalities of in situ chemo-
therapy for recurrent/resistant retinoblastoma according to
exclusive inclusion criteria, namely intra-arterial melphalan
chemotherapy, peri-ocular topotecan, and intravitreal injec-
tion of melphalan.
Specifically, the indication for intravitreal chemotherapy is
considered in this protocol when the relapsed tumor burden
is mostly vitreal, with or without subretinal seeds, provided
that its source is accessible to focal treatment.
If validated, IViC will not only be useful as salvage treat-
ment for recurrent or resistant vitreous seeds, but also as a
prophylactic measure in cases of iatrogenic seeding after
photocoagulation and plaque surgery, or for group B eyes
with ruptured internal limiting membrane (as assessed by
fluorescein angiography), i.e. presumptive submicroscopic
infraclinical vitreous disease at presentation. In addition, con-
firmation of IViC safety will pave the way for the development
and trials with novel, possibly customized molecules.
Finally, we want to emphasize that although IViC does not
replace standard treatment care for groups C and D eyes, we
expect that the addition of front-line IViC to state of the art
treatment in eligible groups C and D eyes may significantly
reduce the exposure to systemic chemotherapy, as well as
the indications for enucleation and/or EBR.Conflict of interest
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